Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- Author
- SALLES, Gilles1 ; SEYMOUR, John Francis2 ; CABALLERO, Dolores10 ; HAIOUN, Corinne11 ; PEDERSEN, Lars Moller12 ; DELMER, Alain13 ; SIMPSON, David14 ; LEPPA, Sirpa15 ; SOUBEYRAN, Pierre16 ; HAGENBEEK, Anton17 ; CASASNOVAS, Olivier18 ; INTRAGUMTOMCHAI, Tanin19 ; OFFNER, Fritz3 ; FERME, Christophe20 ; DA SILVA, Maria Gomes21 ; SEBBAN, Catherine22 ; LISTER, Andrew23 ; ESTELL, Jane A24 ; MILONE, Gustavo25 ; SONET, Anne26 ; MENDILA, Myriam27 ; COIFFIER, Bertrand1 ; TILLY, Hervé28 ; LOPEZ-GUILLERMO, Armando4 ; BELADA, David5 ; XERRI, Luc6 ; FEUGIER, Pierre7 ; BOUABDALLAH, Réda6 ; CATALANO, John Vincent8 ; BRICE, Pauline9
[1] Hospices Civils de Lyon, Université Claude Bernard, UMR CNRS5239, Pierre-Bénite, France
[2] Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia
[3] Ghent University, Ghent, Belgium
[4] Hospital Clinic, Barcelona, Spain
[5] Charles University in Prague, Faculty of Medicine, University Hospital Hradec Králové, Prague, Czech Republic
[6] Institut Paoli Calmettes, Marseille, France
[7] CHU de Nancy, Université Henri Poincaré, Nancy, France
[8] Frankston Hospital, Frankston, VIC, Australia
[9] Hôpital Saint-Louis, AP-HP, Paris, France
[10] Universitario de Salamanca, Salamanca, Spain
[11] Hôpital Henri Mondor, AP-HP, Créteil, France
[12] Odense University Hospital, Odense, Denmark
[13] CHU de Reims, Reims, France
[14] North Shore Hospital, Auckland, New Zealand
[15] Helsinki University Central Hospital, Helsinki, Finland
[16] Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux, France
[17] Academic Medical Centre, Amsterdam, Netherlands
[18] CHU de Dijon, Dijon, France
[19] Chulalongkorn University, Bangkok, Thailand
[20] Institut de Cancérologie Gustave Roussy, Villejuif, France
[21] Portuguese Institute of Oncology, Lisbon, Portugal
[22] Centre Léon Bérard, Lyon, France
[23] Centre for Medical Oncology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
[24] Concord Hospital, Concord, NSW, Australia
[25] Fundaleu, Buenos Aires, Argentina
[26] Mont-Godinne, Yvoir, Belgium
[27] F Hoffmann-La Roche, Basel, Switzerland
[28] Centre Henri Becquerel, Rouen, France - Source
Lancet (British edition). 2011, Vol 377, Num 9759, pp 42-51, 10 p ; ref : 33 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Anticorps monoclonal Association médicamenteuse Chimiothérapie Essai clinique phase III Essai clinique Haut Homme Immunodépresseur Immunomodulateur Immunothérapie Lymphome folliculaire Maintenance Malade Médecine Rituximab Traitement Tumeur Anti-CD20 Antigène CD20 Essai randomisé contrôlé Hémopathie lymphoïde B Hémopathie maligne lymphoïde Cancer Hémopathie maligne Lymphome non hodgkinien Syndrome lymphoprolifératif
- Keyword (en)
- Antineoplastic agent Monoclonal antibody Drug combination Chemotherapy Phase III trial Clinical trial High Human Immunosuppressive agent Immunomodulator Immunotherapy Follicular lymphoma Maintenance Patient Medicine Rituximab Treatment Tumor Randomized controlled trial B cell neoplasm Lymphoid neoplasm Cancer Malignant hemopathy Non Hodgkin lymphoma Lymphoproliferative syndrome
- Keyword (es)
- Anticanceroso Anticuerpo monoclonal Asociación medicamentosa Quimioterapia Ensayo clínico fase III Ensayo clínico Alto Hombre Inmunodepresor Inmunomodulador Inmunoterapia Linfoma folicular Mantenimiento Enfermo Medicina Rituximab Tratamiento Tumor Ensayo aleatorio controlado Cáncer Hemopatía maligna Linfoma no Hodgkin Linfoproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Generalities in medical sciences
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 23706685
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(10)62175-7 
https://dx.doi.org/10.1016/S0140-6736(10)62175-7
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"377\";s:8:\"\u0000*\u0000issue\";s:4:\"9759\";s:8:\"\u0000*\u0000spage\";s:2:\"42\";s:8:\"\u0000*\u0000epage\";s:2:\"51\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SALLES\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gilles\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:29:{i:0;s:21:\"SEYMOUR, John Francis\";i:1;s:18:\"CABALLERO, Dolores\";i:2;s:15:\"HAIOUN, Corinne\";i:3;s:21:\"PEDERSEN, Lars Moller\";i:4;s:13:\"DELMER, Alain\";i:5;s:14:\"SIMPSON, David\";i:6;s:12:\"LEPPA, Sirpa\";i:7;s:17:\"SOUBEYRAN, Pierre\";i:8;s:16:\"HAGENBEEK, Anton\";i:9;s:19:\"CASASNOVAS, Olivier\";i:10;s:22:\"INTRAGUMTOMCHAI, Tanin\";i:11;s:13:\"OFFNER, Fritz\";i:12;s:17:\"FERME, Christophe\";i:13;s:21:\"DA SILVA, Maria Gomes\";i:14;s:17:\"SEBBAN, Catherine\";i:15;s:14:\"LISTER, Andrew\";i:16;s:14:\"ESTELL, Jane A\";i:17;s:15:\"MILONE, Gustavo\";i:18;s:11:\"SONET, Anne\";i:19;s:15:\"MENDILA, Myriam\";i:20;s:18:\"COIFFIER, Bertrand\";i:21;s:13:\"TILLY, Herv\u00e9\";i:22;s:24:\"LOPEZ-GUILLERMO, Armando\";i:23;s:13:\"BELADA, David\";i:24;s:10:\"XERRI, Luc\";i:25;s:15:\"FEUGIER, Pierre\";i:26;s:18:\"BOUABDALLAH, R\u00e9da\";i:27;s:22:\"CATALANO, John Vincent\";i:28;s:14:\"BRICE, Pauline\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"377\";s:8:\"\u0000*\u0000issue\";s:4:\"9759\";s:8:\"\u0000*\u0000spage\";s:2:\"42\";s:8:\"\u0000*\u0000epage\";s:2:\"51\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SALLES\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gilles\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:29:{i:0;s:21:\"SEYMOUR, John Francis\";i:1;s:18:\"CABALLERO, Dolores\";i:2;s:15:\"HAIOUN, Corinne\";i:3;s:21:\"PEDERSEN, Lars Moller\";i:4;s:13:\"DELMER, Alain\";i:5;s:14:\"SIMPSON, David\";i:6;s:12:\"LEPPA, Sirpa\";i:7;s:17:\"SOUBEYRAN, Pierre\";i:8;s:16:\"HAGENBEEK, Anton\";i:9;s:19:\"CASASNOVAS, Olivier\";i:10;s:22:\"INTRAGUMTOMCHAI, Tanin\";i:11;s:13:\"OFFNER, Fritz\";i:12;s:17:\"FERME, Christophe\";i:13;s:21:\"DA SILVA, Maria Gomes\";i:14;s:17:\"SEBBAN, Catherine\";i:15;s:14:\"LISTER, Andrew\";i:16;s:14:\"ESTELL, Jane A\";i:17;s:15:\"MILONE, Gustavo\";i:18;s:11:\"SONET, Anne\";i:19;s:15:\"MENDILA, Myriam\";i:20;s:18:\"COIFFIER, Bertrand\";i:21;s:13:\"TILLY, Herv\u00e9\";i:22;s:24:\"LOPEZ-GUILLERMO, Armando\";i:23;s:13:\"BELADA, David\";i:24;s:10:\"XERRI, Luc\";i:25;s:15:\"FEUGIER, Pierre\";i:26;s:18:\"BOUABDALLAH, R\u00e9da\";i:27;s:22:\"CATALANO, John Vincent\";i:28;s:14:\"BRICE, Pauline\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"377\";s:8:\"\u0000*\u0000issue\";s:4:\"9759\";s:8:\"\u0000*\u0000spage\";s:2:\"42\";s:8:\"\u0000*\u0000epage\";s:2:\"51\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SALLES\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gilles\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:29:{i:0;s:21:\"SEYMOUR, John Francis\";i:1;s:18:\"CABALLERO, Dolores\";i:2;s:15:\"HAIOUN, Corinne\";i:3;s:21:\"PEDERSEN, Lars Moller\";i:4;s:13:\"DELMER, Alain\";i:5;s:14:\"SIMPSON, David\";i:6;s:12:\"LEPPA, Sirpa\";i:7;s:17:\"SOUBEYRAN, Pierre\";i:8;s:16:\"HAGENBEEK, Anton\";i:9;s:19:\"CASASNOVAS, Olivier\";i:10;s:22:\"INTRAGUMTOMCHAI, Tanin\";i:11;s:13:\"OFFNER, Fritz\";i:12;s:17:\"FERME, Christophe\";i:13;s:21:\"DA SILVA, Maria Gomes\";i:14;s:17:\"SEBBAN, Catherine\";i:15;s:14:\"LISTER, Andrew\";i:16;s:14:\"ESTELL, Jane A\";i:17;s:15:\"MILONE, Gustavo\";i:18;s:11:\"SONET, Anne\";i:19;s:15:\"MENDILA, Myriam\";i:20;s:18:\"COIFFIER, Bertrand\";i:21;s:13:\"TILLY, Herv\u00e9\";i:22;s:24:\"LOPEZ-GUILLERMO, Armando\";i:23;s:13:\"BELADA, David\";i:24;s:10:\"XERRI, Luc\";i:25;s:15:\"FEUGIER, Pierre\";i:26;s:18:\"BOUABDALLAH, R\u00e9da\";i:27;s:22:\"CATALANO, John Vincent\";i:28;s:14:\"BRICE, Pauline\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"377\";s:8:\"\u0000*\u0000issue\";s:4:\"9759\";s:8:\"\u0000*\u0000spage\";s:2:\"42\";s:8:\"\u0000*\u0000epage\";s:2:\"51\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SALLES\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gilles\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:29:{i:0;s:21:\"SEYMOUR, John Francis\";i:1;s:18:\"CABALLERO, Dolores\";i:2;s:15:\"HAIOUN, Corinne\";i:3;s:21:\"PEDERSEN, Lars Moller\";i:4;s:13:\"DELMER, Alain\";i:5;s:14:\"SIMPSON, David\";i:6;s:12:\"LEPPA, Sirpa\";i:7;s:17:\"SOUBEYRAN, Pierre\";i:8;s:16:\"HAGENBEEK, Anton\";i:9;s:19:\"CASASNOVAS, Olivier\";i:10;s:22:\"INTRAGUMTOMCHAI, Tanin\";i:11;s:13:\"OFFNER, Fritz\";i:12;s:17:\"FERME, Christophe\";i:13;s:21:\"DA SILVA, Maria Gomes\";i:14;s:17:\"SEBBAN, Catherine\";i:15;s:14:\"LISTER, Andrew\";i:16;s:14:\"ESTELL, Jane A\";i:17;s:15:\"MILONE, Gustavo\";i:18;s:11:\"SONET, Anne\";i:19;s:15:\"MENDILA, Myriam\";i:20;s:18:\"COIFFIER, Bertrand\";i:21;s:13:\"TILLY, Herv\u00e9\";i:22;s:24:\"LOPEZ-GUILLERMO, Armando\";i:23;s:13:\"BELADA, David\";i:24;s:10:\"XERRI, Luc\";i:25;s:15:\"FEUGIER, Pierre\";i:26;s:18:\"BOUABDALLAH, R\u00e9da\";i:27;s:22:\"CATALANO, John Vincent\";i:28;s:14:\"BRICE, Pauline\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(10)62175-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"377\";s:8:\"\u0000*\u0000issue\";s:4:\"9759\";s:8:\"\u0000*\u0000spage\";s:2:\"42\";s:8:\"\u0000*\u0000epage\";s:2:\"51\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SALLES\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gilles\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:29:{i:0;s:21:\"SEYMOUR, John Francis\";i:1;s:18:\"CABALLERO, Dolores\";i:2;s:15:\"HAIOUN, Corinne\";i:3;s:21:\"PEDERSEN, Lars Moller\";i:4;s:13:\"DELMER, Alain\";i:5;s:14:\"SIMPSON, David\";i:6;s:12:\"LEPPA, Sirpa\";i:7;s:17:\"SOUBEYRAN, Pierre\";i:8;s:16:\"HAGENBEEK, Anton\";i:9;s:19:\"CASASNOVAS, Olivier\";i:10;s:22:\"INTRAGUMTOMCHAI, Tanin\";i:11;s:13:\"OFFNER, Fritz\";i:12;s:17:\"FERME, Christophe\";i:13;s:21:\"DA SILVA, Maria Gomes\";i:14;s:17:\"SEBBAN, Catherine\";i:15;s:14:\"LISTER, Andrew\";i:16;s:14:\"ESTELL, Jane A\";i:17;s:15:\"MILONE, Gustavo\";i:18;s:11:\"SONET, Anne\";i:19;s:15:\"MENDILA, Myriam\";i:20;s:18:\"COIFFIER, Bertrand\";i:21;s:13:\"TILLY, Herv\u00e9\";i:22;s:24:\"LOPEZ-GUILLERMO, Armando\";i:23;s:13:\"BELADA, David\";i:24;s:10:\"XERRI, Luc\";i:25;s:15:\"FEUGIER, Pierre\";i:26;s:18:\"BOUABDALLAH, R\u00e9da\";i:27;s:22:\"CATALANO, John Vincent\";i:28;s:14:\"BRICE, Pauline\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:179:\"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
